

Resource Summary Report

Generated by [RRID](#) on Sep 10, 2026

Recombinant Anti-Granzyme B antibody [EPR22645-206]

RRID:AB_2860567

Type: Antibody

Proper Citation

Abcam Cat# ab255598, RRID:AB_2860567

Antibody Information

URL: http://antibodyregistry.org/AB_2860567

Proper Citation: Abcam Cat# ab255598, RRID:AB_2860567

Target Antigen: Granzyme B

Host Organism: rabbit

Clonality: recombinant

Comments: Applications: WB, IHC-P, IHC-Fr, IP

Antibody Name: Recombinant Anti-Granzyme B antibody [EPR22645-206]

Description: This recombinant targets Granzyme B

Target Organism: Human, Mouse

Clone ID: EPR22645-206

Antibody ID: AB_2860567

Vendor: Abcam

Catalog Number: ab255598

Record Creation Time: 20231110T032037+0000

Record Last Update: 20260829T205430+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Granzyme B antibody [EPR22645-206].

No alerts have been found for Recombinant Anti-Granzyme B antibody [EPR22645-206].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Fukugaki A, et al. (2026) Enhancing Immunotherapeutic Response in Colorectal Cancer with a Neuropilin 1-Targeting Tumor-Penetrating Peptide. Cancer research communications, 6(6), 1364.

Zhang Y, et al. (2026) Targeting EP2/EP4-driven expansion of suppressive VSIG4high macrophages overcomes immunotherapy resistance in colorectal cancer. Cell reports, 45(6), 117450.

Yao L, et al. (2026) Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy. Cell reports. Medicine, 102928.

Zhang H, et al. (2026) Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors. Cell reports. Medicine, 7(2), 102545.

Shang X, et al. (2026) Dual PD-1/IL-2R?? targeting restores CD8+ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC. Cell reports. Medicine, 7(3), 102633.

Liu X, et al. (2026) Distinct Inflammatory Cytotoxic T Lymphocyte Populations Mediate PD-1 Blockade-Induced Immune-Related Adverse Events in Multiple Organs. Cancer research, 86(15), 3720.

Wang Z, et al. (2026) PTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tumor immune escape in ovarian cancer. Cell reports, 45(4), 117198.

Chen C, et al. (2026) B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity. Cancer cell.

Dong Z, et al. (2026) Engineering oral commensal nanovaccines to activate mucosal-systemic immune cascades against tumor. Cell host & microbe.

Zhang Y, et al. (2026) Dual blockade of PD-1 and NKG2A prevents NK cell senescence and reprograms the immunosuppressive microenvironment in pancreatic cancer. Cell reports, 45(7), 117583.

Bian Q, et al. (2025) Maternal natural killer cells drive neuroimmune disorders in offspring through aberrant secretion of extracellular granzyme B. *Immunity*, 58(6), 1502.

Li X, et al. (2025) The Dynamically Evolving Cell States and Ecosystem from Benign Nevi to Melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(12), 2478.

Zhou Q, et al. (2025) Vorapaxar enhanced mitochondria-associated ferroptosis primes cancer immunotherapy via targeting FOXO1/HMOX1 axis. *Cell reports. Medicine*, 102371.

Xu Y, et al. (2025) Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy. *Cell*.

Wang M, et al. (2025) Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors. *Cancer discovery*, 15(9), 1883.

Tang R, et al. (2025) Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. *Gastroenterology*, 169(4), 615.

Chen D, et al. (2025) Ce6 derivative photodynamic therapy triggers PANoptosis and enhances antitumor immunity with LAG3 blockade in cutaneous squamous cell carcinoma. *Cell reports. Medicine*, 6(7), 102239.

Kim S, et al. (2025) Multiregional single-cell transcriptomics reveals an association between partial EMT and immunosuppressive states in oral squamous cell carcinoma. *iScience*, 28(9), 112988.

Dalangood S, et al. (2025) Cancer-associated adipocytes mediate CD8+T cell dysfunction via FGF21-driven lipolysis. *Cell reports*, 44(11), 116526.

Liu Y, et al. (2025) Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development. *Cell metabolism*, 37(9), 1907.